These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 38684648)
21. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809 [TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2. Dong S; Li Z; Kong J; Wu S; Gao J; Sun W Int J Hyperthermia; 2022; 39(1):888-896. PubMed ID: 35848416 [TBL] [Abstract][Full Text] [Related]
23. Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy. Yang L; Wang Y; Song Y; Li Z; Lei L; Li H; He B; Cao J; Gao H J Control Release; 2024 Jun; 370():354-366. PubMed ID: 38685387 [TBL] [Abstract][Full Text] [Related]
24. Arsenic trioxide induces innate immune response and inflammatory response in chicken liver via cGAS-STING/NF-κB pathway. Pan H; Zhou L; Zou J; Sun J; You Y; Zhong G; Liao J; Zhang H; Tang Z; Hu L Comp Biochem Physiol C Toxicol Pharmacol; 2024 Dec; 286():110017. PubMed ID: 39218134 [TBL] [Abstract][Full Text] [Related]
25. Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide. Cui L; Gao B; Cao Z; Chen X; Zhang S; Zhang W Mol Med Rep; 2016 Mar; 13(3):2032-8. PubMed ID: 26781180 [TBL] [Abstract][Full Text] [Related]
26. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo. Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700 [TBL] [Abstract][Full Text] [Related]
27. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma. Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633 [TBL] [Abstract][Full Text] [Related]
28. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma. Zhang F; Duan J; Song H; Yang L; Zhou M; Wang X Drug Dev Res; 2021 May; 82(3):430-439. PubMed ID: 33244794 [TBL] [Abstract][Full Text] [Related]
29. Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation. Wei M; Wang X; Mo Y; Kong C; Zhang M; Qiu G; Tang Z; Chen J; Wu F Int J Nanomedicine; 2024; 19():7215-7236. PubMed ID: 39050875 [TBL] [Abstract][Full Text] [Related]
30. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. Liu ZM; Tseng JT; Hong DY; Huang HS Biochem J; 2011 Sep; 438(2):349-58. PubMed ID: 21649584 [TBL] [Abstract][Full Text] [Related]
31. Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma. Liu J; Li X; Chen J; Zhang X; Guo J; Gu J; Mei C; Xiao Y; Peng C; Liu J; Hu X; Zhang K; Li D; Zhou B ACS Appl Mater Interfaces; 2023 Feb; 15(5):6260-6273. PubMed ID: 36695492 [TBL] [Abstract][Full Text] [Related]
32. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway. Ma H; Kang Z; Foo TK; Shen Z; Xia B Hepatology; 2023 Jan; 77(1):33-47. PubMed ID: 35006619 [TBL] [Abstract][Full Text] [Related]
33. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma. Chen A; Yu Z; Ma N; Lu X; Zhang Y; Xu W; Wang Y; Xie J; Qin Y; Mo G; Wu S; Hou J; Zhu W Cancer Immunol Immunother; 2024 Feb; 73(3):49. PubMed ID: 38349553 [TBL] [Abstract][Full Text] [Related]
34. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models. Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945 [TBL] [Abstract][Full Text] [Related]
35. BIBR1532 combined with radiotherapy induces ferroptosis in NSCLC cells and activates cGAS-STING pathway to promote anti-tumor immunity. Bao Y; Pan Z; Zhao L; Qiu J; Cheng J; Liu L; Qian D J Transl Med; 2024 May; 22(1):519. PubMed ID: 38816831 [TBL] [Abstract][Full Text] [Related]
36. Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death. Guo Y; Qian R; Li Z; Lv T; Yang C; Li W; Pan T; Hou X; Wang Z Life Sci; 2024 Jul; 348():122687. PubMed ID: 38718856 [TBL] [Abstract][Full Text] [Related]
37. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression. Lv T; Xiong X; Yan W; Liu M; Xu H; He Q J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688553 [TBL] [Abstract][Full Text] [Related]
38. Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy. Wang L; Bi S; Li Z; Liao A; Li Y; Yang L; Zhou X; Gao Y; Liu X; Zou Y; Zhang X; Shi J; Yu S; Yu Z; Guo J Biomaterials; 2025 Feb; 313():122766. PubMed ID: 39180916 [TBL] [Abstract][Full Text] [Related]
39. Hypoxia-induced RNASEH2A limits activation of cGAS-STING signaling in HCC and predicts poor prognosis. Zhao F; Liu A; Gong X; Chen H; Wei J; Chen B; Chen S; Yang R; Fan Y; Mao R Tumori; 2022 Feb; 108(1):63-76. PubMed ID: 34165025 [TBL] [Abstract][Full Text] [Related]
40. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. Rangwala F; Williams KP; Smith GR; Thomas Z; Allensworth JL; Lyerly HK; Diehl AM; Morse MA; Devi GR BMC Cancer; 2012 Sep; 12():402. PubMed ID: 22963400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]